Quinolone therapy in intensive care unit settings.
Three fluoroquinolone antimicrobials (norfloxacin, ciprofloxacin, and ofloxacin) could be used to prevent or treat infections in intensive care unit patients. All of these fluoroquinolones are particularly active against Gram-negative, aerobic bacteria. However, the pharmacokinetic properties of each fluoroquinolone are unique. Furthermore, only ciprofloxacin and ofloxacin are available for intravenous administration. Based on current, available information: a) fluoroquinolones are not endorsed for inclusion in selective decontamination protocols; b) fluoroquinolones are endorsed for empiric therapy of suspected Gram-negative bacterial infections based on local microorganism susceptibility patterns; and c) fluoroquinolones are endorsed for treatment of microbiologically documented infections based on their distribution properties, low rate of toxicity, and rapid bactericidal effect.
Beam
T R
TR
Buffalo Veterans Administration Medical Center, State University of New York at Buffalo 14215.
D000284:Administration, Oral; D000368:Aged; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000600:supply & distribution / Q000627:therapeutic use*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000493:pharmacokinetics / Q000600:supply & distribution / Q000627:therapeutic use*; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000600:supply & distribution / Q000627:therapeutic use*; D014018:Tissue Distribution
D002939:Ciprofloxacin; D015242:Ofloxacin; D009643:Norfloxacin